Advertisement

Search Results

Advertisement



Your search for Caroline Helwick matches 2403 pages

Showing 751 - 800


lymphoma

Phase II PRIMO Dose-Optimization Trial of Duvelisib in Peripheral T-Cell Lymphoma

Researchers at the ASH Annual Meeting and Exposition reported high response rates in patients with relapsed peripheral T-cell lymphoma after treatment with single-agent duvelisib, a dual PI3K inhibitor.1  Barbara Pro, MD, of Robert H. Lurie Comprehensive Cancer Center, Northwestern University...

lymphoma

Expert Point of View: Deepa Jagadeesh, MD, MPH

“Although some B-cell lymphomas are highly curable, this goal remains elusive for most T-cell lymphomas (TCL). Refractory and relapsed disease post induction therapy remains a major challenge in management,” said Deepa Jagadeesh, MD, MPH, Assistant Professor, Cleveland Clinic Lerner College of...

lymphoma

Allogeneic Stem Cell Transplant Improves Survival in Peripheral T-Cell Lymphoma

In a large retrospective analysis of allogeneic transplant for relapsed or refractory peripheral T-cell lymphoma (PTCL), more than half the patients studied were alive at 5 years, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 “In the...

breast cancer

Expert Point of View: Neil M. Iyengar, MD

Neil M. Iyengar, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, has researched the links between breast cancer and lifestyle. He provided comments on these two abstracts from the 2020 San Antonio Breast Cancer Symposium (SABCS) for The ASCO Post. “These two...

breast cancer

Can a High-Carbohydrate Diet Increase the Risk for Breast Cancer?

A growing body of evidence is showing a strong association between diet and breast cancer risk and survival, particularly high glycemic load and sugar intake. Two large population studies at the 2020 San Antonio Breast Cancer Symposium supported these observations.1,2 Findings from the Nurses’...

lymphoma
immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other CAR T-cell products being evaluated for indolent...

lymphoma
immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...

gastrointestinal cancer
immunotherapy

Expert Point of View: John C. Krauss, MD

The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to dostarlimab were demonstrated in a “relatively...

gastrointestinal cancer
immunotherapy

Anti–PD-1 Antibody Dostarlimab Active in Mismatch Repair–Deficient Gastrointestinal Tumors

Dostarlimab, a monoclonal antibody targeting PD-1, showed antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported at the 2021 Gastrointestinal Cancers Symposium by Thierry André, MD, of Sorbonne University and Saint-Antoine...

colorectal cancer

Expert Point of View: Michael J. Overman, MD

The study’s invited discussant, Michael J. Overman, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, said the findings of the study presented by Henriksen et al1 add to a convincing body of data showing that “the use of circulating...

colorectal cancer

Predicting Postoperative Recurrence in Stage I to III Colorectal Cancer With Circulating Tumor DNA

Patients with stage I to III colorectal cancer who have a high risk for recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA proved more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...

hepatobiliary cancer

Expert Point of View: Rachna T. Shroff, MD

Invited discussant of the ClarIDHy trial, Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said positive findings for ivosidenib support the notion that “biliary cancer is a perfect example of...

hepatobiliary cancer

ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Benefits Survival in Cholangiocarcinoma

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...

lung cancer
immunotherapy

Nivolumab Monotherapy Improves Survival in Patients With Relapsed Malignant Mesothelioma

In patients with relapsed malignant mesothelioma, treatment with single-agent nivolumab led to a significant improvement in both overall and progression-free survival in the phase III CONFIRM trial. These findings were presented by Dean A. Fennell, FRCP, PhD, Professor and Chair of Thoracic Medical ...

lung cancer
immunotherapy

LCMC3 Trial: Neoadjuvant Atezolizumab for Patients With Stage IB to IIIB Resectable Lung Cancer

Neoadjuvant treatment with single-agent atezolizumab for patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and pathologic complete response rate of 7% in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study. The findings were...

lung cancer
immunotherapy

Negative Findings in KEYNOTE-598: Ipilimumab Adds No Benefit to Pembrolizumab as First-Line Therapy for NSCLC With High PD-L1 Expression

In the phase III KEYNOTE-598 study, the addition of ipilimumab to pembrolizumab increased toxicity without boosting efficacy as first-line therapy for metastatic non–small cell lung cancer (NSCLC) in patients with high expression of PD-L1, according to research presented at International...

lung cancer

Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC

The phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in patients with advanced non–small cell lung cancer (NSCLC). In a follow-up to phase I data, the phase II cohort of the study has now shown a durable response rate of 37.1%, a disease control rate...

breast cancer

Expert Point of View: C. Kent Osborne, MD, and Ruth M. O’Regan, MD

Commentary for monarchE and PENELOPE-B was provided by C. Kent Osborne, MD, and Ruth M. O’Regan, MD, respectively. Dr. Osborne is Professor of Medicine, Hematology, and Oncology and the Dudley and Tina Sharp Chair for Cancer Research at Baylor College of Medicine, as well as Founding Director of...

breast cancer

A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer

The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...

multiple myeloma
immunotherapy

Expert Point of View: Sagar Lonial, MD, and Adam D. Cohen, MD

The studies of ALLO-715 “off-the-shelf” CAR T-cell therapy and bb21217 impressed two experts in the field. Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, and Adam D. Cohen, MD, ...

multiple myeloma
immunotherapy

Novel Anti-BCMA CAR T-Cell Therapies Show Activity in Myeloma

In the treatment of relapsed or refractory multiple myeloma, chimeric antigen receptor (CAR) T-cell therapies with unique characteristics, still targeting B-cell maturation antigen (BCMA), are looking promising. At the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition,...

multiple myeloma

Expert Point of View: Suzanne Lentzsch, MD, PhD

IFM 2009 showed that autologous stem cell transplant (ASCT) combined with lenalidomide, bortezomib, and dexamethasone (RVd) results in a significantly better progression-free survival than RVd alone in newly diagnosed patients with myeloma.1 “The data favor immediate ASCT, as transplant resulted in ...

multiple myeloma

Long-Term Follow-up of IFM 2009 Confirms Benefit of Front-Line Transplant in Myeloma

The benefit of autologous transplantation in newly diagnosed multiple myeloma has been confirmed by follow-up of the IFM 2009 trial, reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition by Aurore Perrot, MD, PhD, Assistant Professor of Hematology at the Cancer...

breast cancer

Expert Point of View: William Gradishar, MD

Thoughts on oral taxanes—and in particular, tesetaxel—were provided by William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center. Dr. Gradishar commented that...

breast cancer

Oral Taxanes Moving Forward in Metastatic Breast Cancer

Positive results have now been reported in phase III trials of two oral taxanes in the treatment of metastatic breast cancer. At the 2020 San Antonio Breast Cancer Symposium, treatment with tesetaxel and reduced-dose capecitabine resulted in an improvement in progression-free survival of about 3...

breast cancer

Expert Point of View: Cristina Saura Manich, MD, PhD

Study discussant Cristina Saura Manich, MD, PhD, Head of the Breast Cancer Program at the Vall d’Hebron University Hospital in Barcelona, offered some thoughts as to the underlying mechanism of benefit from trilaciclib in the phase II study reported by Dr. Joyce A. O’Shaugnessy. Trilaciclib is a...

breast cancer

Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer

The intravenous administration of trilaciclib, the first-in-class reversible inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), given with chemotherapy, led to a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer, compared with...

multiple myeloma
immunotherapy

Belantamab Mafodotin-blmf in Multiple Myeloma: Number of Prior Treatments No Hindrance to Efficacy

A post hoc analysis of the phase II DREAMM-2 trial showed single-agent belantamab mafodotin-blmf to be efficacious and tolerable in patients with relapsed  or refractory multiple myeloma treated with at least three prior therapies, investigators reported at the 2020 American Society of Hematology...

gastrointestinal cancer
colorectal cancer
gastroesophageal cancer

Anti–PD-1 Therapy Dostarlimab for dMMR Gastrointestinal Cancers: Safety and Efficacy Examined

Dostarlimab, a monoclonal antibody targeting PD-1, showed strong and durable antitumor activity in patients with mismatch repair–deficient (dMMR) gastrointestinal tumors in the phase I GARNET study, reported Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Bemarituzumab Plus Chemotherapy Improves Outcomes in Advanced Gastric/Gastroesophageal Junction Cancer

Gastric cancer has a new target: fibroblast growth factor receptor 2b (FGFR2b). Targeting FGFR2b with bemarituzumab plus chemotherapy led to clinically meaningful and statistically significant improvements in progression-free survival, overall survival, and response rates in the randomized phase II ...

colorectal cancer

Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA

Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA was more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...

hepatobiliary cancer

IDH Inhibitor Ivosidenib Improves Overall Survival in Previously Treated Patients With Cholangiocarcinoma: ClarIDHy Trial

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months compared with placebo in previously treated patients with advanced IDH1-mutated cholangiocarcinoma. Researchers presented results from the global phase III ClarIDHy trial at the 2021...

multiple myeloma
immunotherapy

Expert Point of View: Ajay K. Nooka, MD, MPH

Ajay K. Nooka, MD, MPH, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be among...

multiple myeloma
immunotherapy

New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma

B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging (BiTE) antibodies with novel targets are also achieving promising results. Studies presented at the 2020 American Society of Hematology (ASH)...

multiple myeloma
immunotherapy

Expert Point of View: Sagar Lonial, MD

Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO trial for The ASCO Post. “APOLLO is a highly awaited study, as the use of daratumumab plus...

multiple myeloma
immunotherapy

Subcutaneous Daratumumab Meets Primary Endpoint in APOLLO Trial in Myeloma

The first phase III study to evaluate the subcutaneous form of daratumumab has met its primary endpoint, investigators of the APOLLO trial reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 The triplet of daratumumab, pomalidomide, and low-dose dexamethasone ...

Expert Point of View: Cathy Eng, MD

Cathy Eng, MD, the David H. Johnson Chair in Surgical and Medical Oncology, Co-Leader of the Gastrointestinal (GI) Cancer Research Program, and Co-Director of GI Oncology at Vanderbilt-Ingram Cancer Center in Nashville, as well as Vice Chair of the SWOG GI Committee, said she found the study’s...

colorectal cancer

Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer

To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...

issues in oncology
global cancer care

European Experts Tackle HPV-Related Cancers

The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...

issues in oncology
global cancer care

Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win

Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...

issues in oncology
global cancer care

Addressing Inequality in Cancer Care on a Global Scale

It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...

skin cancer

Intratumoral Injections May Boost Neoadjuvant Response in Resectable Melanoma

Studies reported at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which was held virtually, showed promise for the use of intratumoral injections of novel immunotherapies in treating advanced, resectable melanoma. In the 3-year interim analysis of a global phase II randomized...

Expert Point of View: Omid Hamid, MD

Omid Hamid, MD, Chief of Research/Immuno-Oncology at The Angeles Clinic & Research Institute and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on the investigational use of bempegaldesleukin in melanoma. “The role of interleukin-2 [Il-2]...

skin cancer

Novel Combination Under Study in First-Line Treatment of Metastatic Melanoma

A first-line regimen combining the novel interleukin-2 (Il-2) agonist bempegaldesleukin (NKTR-214) with nivolumab showed encouraging clinical activity in patients with metastatic melanoma in the phase I/II PIVOT-02 trial, according to a presentation during the 2020 Annual Meeting of the Society for ...

Expert Point of View: Robert A. Brodsky, MD

Robert A. Brodsky, MD, Professor of Medicine and Oncology and Director of the Division of Hematology, Johns Hopkins School of Medicine, Baltimore, included this late-breaking abstract among his picks of noteworthy abstracts at the meeting, in a press briefing with journalists. “The researchers...

hematologic malignancies

First Sign of Myeloproliferative Neoplasms May Be in Utero

Genetic mutations linked to myeloproliferative neoplasms emerge in childhood or even in utero, decades before they cause cancer, according to a late-breaking abstract presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 “Our preliminary findings show these...

Expert Point of View: C. Kent Osborne, MD

C. Kent Osborne, MD, Founding Director of the Dan L. Duncan Comprehensive Cancer Center and the Dudley and Tina Sharp Chair for Cancer Research, Baylor College of Medicine, Houston, said in a press briefing that the results of the study were clear, but the explanation for the findings is less so....

breast cancer

RxPONDER: Many Postmenopausal Patients With Node-Positive Breast Cancer Can Avoid Chemotherapy

Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage hormone receptor–positive, HER2-negative breast cancer and node-positive disease.1 The data showed that many postmenopausal women can skip adjuvant chemotherapy, based on ...

hematologic malignancies

Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome, Study Reports

Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...

breast cancer

SABCS 2020: RxPONDER Study Shows Postmenopausal Patients With Node-Positive Breast Cancer May Be Able to Avoid Chemotherapy

Just in are the results of the SWOG S1007 RxPONDER trial, which evaluated the benefit of chemotherapy in women with early-stage, hormone receptor (HR)-positive, node-positive breast cancer. Based on the findings, many postmenopausal women may be able to safely skip adjuvant chemotherapy. However,...

Advertisement

Advertisement




Advertisement